Journal of Infection
Volume 61, Issue 2 , Pages 155-163 , August 2010

Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection

  • E. Moore

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • M.B.J. Beadsworth

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • Tropical and Infectious Disease Unit, Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK
    • ,
  • M. Chaponda

      Affiliations

    • Tropical and Infectious Disease Unit, Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK
    • Malawi-Liverpool Wellcome Trust, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • B. Mhango

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • B. Faragher

      Affiliations

    • Tropical and Infectious Disease Unit, Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK
    • ,
  • J. Njala

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • H.W.C. Hofland

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • J. Davies

      Affiliations

    • Tropical and Infectious Disease Unit, Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK
    • ,
  • I.J. Hart

      Affiliations

    • Liverpool Specialist Virology Centre, Royal Liverpool University Hospital, Liverpool, UK
    • ,
  • N.J. Beeching

      Affiliations

    • Tropical and Infectious Disease Unit, Royal Liverpool University Hospital and Liverpool School of Tropical Medicine, Liverpool, UK
    • ,
  • E.E. Zijlstra

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • ,
  • J.J. van Oosterhout

      Affiliations

    • Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi
    • Malawi-Liverpool Wellcome Trust, College of Medicine, University of Malawi, Blantyre, Malawi
    • Corresponding Author InformationCorresponding author. Department of Medicine, College of Medicine, University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi. Tel.: +265 99 99 22 682.

,Accepted 22 April 2010.

References 

  1. Gilson RJ, Hawkin AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:587–606
  2. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in coinfected patients. J Hepatol. 2006;44:S65–70
  3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heerlen T, et al. Influence of Human Immunodeficiency Virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–569
  4. Omland LH, Jepson P, Skinhoj P, Jørgensen HL, Münster AM, Bangsborg J, et al. The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study. HIV Med. 2009;10:65–71
  5. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicentre Cohort Study (MACS). Lancet. 2002;360:1921–1926
  6. Greub G, Ledergerber B, Battergay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800–1805
  7. Hoffman CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23:1881–1889
  8. Farmer-Millar M, Haley C, Koziel MJ, Rowley CF. Impact of Hepatitis C on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713–720
  9. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471–1477
  10. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis coinfection on response to antiretroviral therapy and HIV disease progression in HIV-NAT Cohort. AIDS. 2004;18:1169–1177
  11. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RDl. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189
  12. den Brinker M, Wit FWNM, Wertheim-van Dillen PME, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902
  13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc. 2000;283:74–80
  14. Law WP, Dore GJ, Duncombe CJ, Boyd MA, Ruxrungtham K, Lange JM, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS. 2003;17:2191–2199
  15. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B coinfection in Asia and Africa. Lancet Infect Dis. 2007;7:402–409
  16. Nyirenda M, Beadsworth MBJ, Stephany P, Haart CA, Hart IJ, Munthali C, et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect. 2008;57:72–77
  17. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain JP. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of Hepatitis B and C viruses. J Med Virol. 2001;65:1–5
  18. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GNl. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr. 2002;31:90–97
  19. van Leth F, Phanuphak P, Ruxrungtham K, Balardi E, Miller S, Gazzard B, et al. Comparison of first line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and Lamivudine: a randomised open-label trial, the 2 NN study. Lancet. 2004;363:1253–1263
  20. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261–1268
  21. Freiman J, Helfert K, Hamrell M, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 1993;7:379–385
  22. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in HIV/ hepatitis B virus coinfected persons in a randomised, controlled study (CAESAR). J Infect Dis. 1999;180:607–613
  23. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV infected patients. Hepatology. 1999;30:1302–1306
  24. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus–infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032–1035
  25. ART-LINC collaboration. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–824
  26. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community based antiretroviral service in South Africa: implications for program design. AIDS. 2005;19:2141–2148
  27. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive early mortality in the first year of treatment in HIV-1 infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses. 2008;24:555–560
  28. National Statistics Office of Malawi. HIV prevalence and associated factors; 2004.
  29. Schnuriger A, Dominguez S, Valantin MA, Tubiana R, Duvivier C, Ghosn J, et al. Early detection of hepatitis C virus infection by use of a new combined antigen–antibody detection assay: potential use for high-risk individuals. J Clin Microbiol. 2006;44:1561–1563
  30. Chamie G, Bonacini M, Bangsberg DR, Stapleton JT, Hall C, Overton ET, et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44:577–583
  31. AIDS Clinical Trial Group Criteria. Table for grading severity of adverse experiences. Section 11 Division of AIDS, National Institute of Allergy & Infectious Diseases; 1992;
  32. Hoffman CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479–1485
  33. Hoffman JH, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21:1301–1308
  34. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49:1268–1273
  35. Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HC, Powderly WG, et al. Sex differences and nevirapine rash. Clin Infect Dis. 2001;32:124–129
  36. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005;40:588–593
  37. Medina-Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakholi B, Walker S, et al., Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART trial). In: 5th International AIDS society conference on HIV pathogenesis, treatment and prevention, Cape Town; 2009 [abstract TuSS104].
  38. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient HIV type 1 viraemia. J Infect Dis. 2007;196:1773–1778
  39. Zacharia R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355–2360
  40. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambuga A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:973–975
  41. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS. 2008;22:1221–1222
  42. Malawi Ministry of Health . Quarterly report National ART Programme, quarter ending 31 December 2007. HIV Unit, Ministry of Health; 2008;
  43. Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, et al. Outcomes of a remote, decentralized health centre-based HIV-AIDS antiretroviral program in Zambia, 2003–2007. J Int Assoc Physicians AIDS Care. 2009;8:60–67

PII: S0163-4453(10)00129-5

doi: 10.1016/j.jinf.2010.04.009

Journal of Infection
Volume 61, Issue 2 , Pages 155-163 , August 2010

Article Tools

* Image Usage & Resolution